First in Human Safety Study of FX-322 in Adults Undergoing Cochlear Implantation

Frequency Therapeutics

Status and phase: Completed; Early Phase 1

Conditions: Hearing Loss

Treatments: Drug: FX-322; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT03300687

FX-322-103

Details and patient eligibility

About

This is a phase 1 safety study performed in male or female adult participants with an established diagnosis of severe to profound sensorineural hearing loss that meets the criteria for cochlear implantation and the participant has already chosen to undergo cochlear implant surgery.

Full description

Approximately 12 participants will be enrolled in the study. Assessed will be safety and tolerability of FX-322 administered by intratympanic injection. Also assessed will be the FX-322 concentration in cochlear fluid (perilymph), the pharmacokinetic (PK) profile of FX-322 to determine the systemic exposure to FX-322.

Enrollment: 9 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Male or female adult subjects with an established diagnosis of severe to profound sensorineural hearing loss audiometric threshold of 80 dB HL or poorer at 500 Hz that meets the criteria for cochlear implantation and the subject has already chosen to undergo cochlear implant surgery.
2. Willingness and ability to comply with scheduled visits, ear examination, drug administration plan, auditory and laboratory tests, study restrictions, and all study procedures.

Other protocol-defined inclusion criteria may apply

Exclusion criteria

1. Persistent perforation of tympanic membrane or other tympanic membrane disorder that would interfere with the delivery and safety assessment of an intra -tympanic medication or reasonably be suspected to affect tympanic membrane healing after injection.
2. Any conductive component defined as air-bone gaps >10 dB at two or more frequencies.

Other protocol-defined exclusion criteria may apply

Trial design

Primary purpose: Other

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: Single Blind

---

9 participants in 2 patient groups, including a placebo group

Active

Active Comparator group

Description:

Subjects will receive FX-322 as an intratympanic injection

Treatment:

Drug: FX-322

Placebo

Placebo Comparator group

Description:

Subjects will receive Placebo as an intratympanic injection

Treatment:

Drug: Placebo